19208-Lung Cancer-NA-445

Lung Cancer

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Address

3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.